Citations

Clear

76 citation(s) found for "Gore, Steven".

A Phase 2 Study of Berzosertib in Combination with Carboplatin compared to Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
Choudhury, Atish D. , Zhong, Caiwei , Xie, Wanling , Kochupurakkal, Bose , Wu, Peter I-Fan , Riaz, Irbaz Bin , Liu, Ruolin , Yang, David D. , Folefac, Edmund , Lee, Daniel , McKay, Rana R. , Pace, Amanda F. , Adalsteinsson, Viktor A. , Kunos, Charles A., Gore, Steven D. , Das, Biswajit , Taplin, Mary‐Ellen , Kochupurakkal, Bose S , Parikh, Mamta , Einstein, David J , Kessler, Elizabeth , Mayer, Tina , McKay, Rana R , Pace, Amanda , Mouw, Kent W , Chen, Li , Adalsteinsson, Viktor A , Van Allen, Eliezer M , Kunos, Charles , Gore, Steven D , Das, Biswasjit , D'Andrea, Alan , Taplin, Mary-Ellen , Shapiro, Geoffrey I , Choudhury, Atish D , Riaz, Irbaz B , Xie, Wanling , Wu, Peter I-Fan , Mouw, Kent W. , D’Andrea, Alan D. , Shapiro, Geoffrey I.

Mayo Clinic

Cancer Research Communications | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1158/2767-9764.crc-26-0488 | PMID 42636061 Get It

Abstract Purpose: Inhibitors of the Ataxia telangiectasia and Rad3-related (ATR) protein kinase, a critical component of the DNA damage repair response, have synergistic anti-cancer activity with platinum compounds in preclinical models. We therefore conducted a Phase 2 study of the ATR inhibitor berzosertib+carboplatin vs. docetaxel+carboplatin in metastatic castration-resistant prostate cancer. Patients and Methods: Patients previously treated with at least one androgen receptor pathway inhibitor and taxane underwent mandatory biopsy and were randomized 1:1 to receive Arm A (docetaxel 60 mg/m2+carboplatin AUC4 day 1; or carboplatin AUC5 if not a docetaxel candidate) or Arm B (berzosertib 90 mg/m2 days 2,9+carboplatin AUC5 day 1) every 21 days. The primary endpoint was overall response rate (ORR; ≥50% PSA decline or radiographic response). Results: Of 73 randomized patients, 65 received protocol treatment: 34 on Arm A (26 docetaxel+carboplatin; 8 carboplatin alone) and 31 on Arm B. Thirteen patients (38%) in Arm A and 20 (65%) in Arm B had ≥Grade 3 treatment-related adverse events (TrAEs). ORR was 15% in Arm A (5/34; 5/26[19%] with docetaxel+carboplatin) and 0% in Arm B (0/31). At interim analysis after 65 of planned 130 patients were treated, enrollment was halted due to futility. Homologous recombination repair deficiency status from tissue and blood did not correlate with clinical outcomes, but ATM-deficiency or high levels of phoshpo-KAP1 detected in tissue was associated with clinical benefit across both arms of the trial. Conclusions: Berzosertib+carboplatin demonstrated lower ORR and more frequent ≥grade 3 TrAEs compared to docetaxel+carboplatin in this heavily pre-treated, biomarker-unselected population. NCT03517969
Multi-center Phase 1 study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)
Chauhan, Aman , Weiss, Heidi L. , Kunos, Charles , Jayswal, Rani , Konda, Bhavana , Soares, Heloisa P. , Li, Daneng , Hálfdánarson, Þorvarður R. , Mulcahy, Mary F. , Jacene, Heather A. , Khurana, Aman , Modak, Rakhi , Christner, Susan M., Das, Biswajit , Gore, Steven D. , Kohn, Elise C. , Anthony, Lowell , Yan, Donglin , Beumer, Jan Hendrik , Christner, Susan M , Wu, Peter I-Fan , Das, Biswasjit , Rubinstein, Larry V , Gore, Steven D , Ivy, S. Percy , Kohn, Elise C , Carson, William E , Anthony, Lowell B , Arnold, Susanne M , Halfdanarson, Thorvardur R , Mulcahy, Mary F , Soares, Heloisa P , Li, Daneng , Wu, Peter I-Fan , Rubinstein, Larry , Carson, William E. , Arnold, Susanne M.

Mayo Clinic

Clinical Cancer Research | July 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1158/1078-0432.ccr-26-0686 | PMID 42518206 Get It

Abstract Introduction: Next generation of Theranostics studies are looking at novel combinations with radiation sensitizers to enhance PRRT’s efficacy. Here, we present safety and efficacy data from a multi-center phase 1 study of a [¹⁷⁷Lu]lutetium-dotatate -triapine combination in patients with GEP-NETs. Methods: The study consisted of two phases (dose escalation and expansion) administering the recommended phase 2 doses (RP2D) for the two agents. All patients received 200 mCi of [¹⁷⁷Lu]lutetium-dotatate on day 1 of four 8-week cycles, in combination with oral triapine administered at assigned dose levels (100 mg, 150 mg or 200mg) from days 1 to 14 of each cycle. Results: A total of 31 (A: 15 ; B: 16 ) patients received treatment. Nine patients experienced dose-limiting toxicities; Grade 3 anemia (n=1), Grade 5 cardiac arrest (n=1), and Grade 4 neutropenia (n=7). Based on the overall safety and pharmacokinetics data, a [¹⁷⁷Lu]lutetium-dotatate (200 mCi) plus triapine (150 mg) dose was selected as the RP2D for the expansion phase. Grade ≥3 treatment related adverse events were observed in 77% patients: anemia (23%), nausea and vomiting (3% ), lymphopenia ( 58%), neutropenia ( 35%) and leukopenia ( 39%). The majority of cytopenias were transient and resolved within two weeks. Among the 28 evaluable patients, the objective response rate (ORR) was 21.4% and the median progression-free survival (mPFS) has not been reached (median follow-up period: 23.7 months). Conclusions: The combination of [¹⁷⁷Lu]lutetium-dotatate (200 mCi) and oral triapine (150 mg D1-14) was well tolerated and demonstrated preliminary activity in patients with well-differentiated GEP-NETs. (NCT04234568).
Real‐world, multi‐omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS)
Sauta, Elisabetta, Lanino, Luca, Bewersdorf, Jan P, Kewan, Tariq, Ali, Najla H. Al, Fenaux, Pierre, Platzbecker, Uwe, Santini, Valeria, Brunner, Andrew M., Kuykendall, Andrew T., Bennett, John M. , Buckstein, Rena, Bejar, Rafael, Carraway, Hetty E., DeZern, Amy E., Hasserjian, R., Loghavi, Sanam, Odenike, Olatoyosi, Padron, Eric , Patnaik, Mrinal M., Stahl, Maximilian, Sekeres, M., Steensma, David P., Savona, Michael R., Taylor, Justin, Xu, Mina L., Sallman, David A., Nimer, Stephen D. , Hourigan, Christopher S., Wei, Andrew H., Riva, Elena , Ventura, Denise, Pinocchio, Nicole, Buizza, Alessandro , Russo, Antonio, D'Amico, Saverio, Delleani, Mattia , Travaglino, Erica , Tentori, Cristina A., Ferrari, Ivan, Crespi, Alessandra, Figini, Giulia , Matteo, Maria Di, Milanesi, Chiara, Castellani, Gastone, Borate, Uma M., Gore, Steven D., Kim, Tae K., Loosdrecht, Arjan A. van de , Daver, N., Wang, Sa A. , Foucar, Kathryn, Iastrebner, Marcelo, Miyazaki, Yasushi, Al‐Kali, Aref, Mittelmann, Moshe, Cluzeau, Thomas , Ades, Lionel, Germing, Ulrich, Garcia‐Manero, Guillermo, Kordasti, Shahram, Haferlach, Torsten, Zeidan, Amer M., consortia, An international study on behalf of GenoMed4all, Synthema, and icMDS, Zeidan, Amer M. , Buizza, Alessandro , Ficara, Francesca , Efficace, Fabio , Diez-Campelo, Maria , Orfao, Alberto , Wang, Sa A , Cluzeau, Thomas , Komrokji, Rami S , Della Porta, Matteo Giovanni , Zeidan, Amer M , Maggioni, Giulia , Todisco, Gabriele , Sauta, Elisabetta , Lanino, Luca , Ball, Somedeb , Bewersdorf, Jan Philipp , Fenaux, Pierre , Platzbecker, Uwe , Santini, Valeria , Xie, Zhuoer , Brunner, Andrew M. , Kuykendall, Andrew , Buckstein, Rena , Bejar, Rafael , Carraway, Hetty E. , Dezern, Amy Elizabeth , Griffiths, Elizabeth A. , Halene, Stephanie , Hasserjian, Robert P. , List, Alan F. , Loghavi, Sanam , Odenike, Olatoyosi , Patnaik, Mrinal M. , Roboz, Gail J. , Sekeres, Mikkael A. , Steensma, David P. , Savona, Michael R. , Sallman, David A. , Hourigan, Christopher S. , Wei, Andrew H. , Campagna, Alessia , Ubezio, Marta , Ventura, Denise , Pinocchio, Nicole , Zampini, Matteo , Russo, Antonio , Pesce, Francesco , D'Amico, Saverio , Asti, Gianluca , Tentori, Cristina Astrid , Ferrari, Ivan , Matteo, Maria Di, Brindisi, Matteo , Manes, Nicla , Crisafulli, Laura , Ficara, Francesca , Castellani, Gastone , Borate, Uma , Efficace, Fabio , Gore, Steven D. , Díez‐Campelo, María , Rozman, Marı́a , Órfão, Alberto , Foucar, Kathryn , Iastrebner, Marcelo , Scheinberg, Phillip , Miyazaki, Yasushi , Madanat, Yazan F. , Al‐Kali, Aref , Mittelman, Moshe , Adès, Lionel , Germing, Ulrich , Garcia‐Manero, Guillermo , Kordasti, Shahram , Haferlach, Torsten , Komrokji, Rami S.

Mayo Clinic

HemaSphere | June 22, 2026 | Volume: 10 | Issue: 6 | Pages: No page available

10.1002/hem3.70406 | PMID 42339339 Get It

Abstract Myelodysplastic syndromes (MDS) are clinically and biologically diverse disorders, emphasizing the need for personalized treatment approaches. The International Working Group for Prognostication of MDS (IWG_PM) recently introduced a molecular classification, referred to as the MDS taxonomy, that categorizes patients into 16 subgroups based on 21 gene mutations, 6 cytogenetic abnormalities, and loss of heterozygosity (LOH) at TP53 and TET2 loci. This study sought to validate and enhance the clinical relevance of the MDS taxonomy by analyzing a large retrospective cohort ( n = 5136) and transcriptomic data from a prospective cohort ( n = 477). The taxonomy successfully identified subgroups with distinct clinical characteristics and disease progression patterns. However, incorporating gene interactions from taxonomy subgroups did not improve the prognostic performance of the Molecular International Prognostic Scoring System (IPSS‐M). We further assessed whether the taxonomy could guide management in patients receiving disease‐modifying therapies. Except for the “ TP53 ‐complex” subgroup, taxonomy classifications were not predictive of hypomethylating agent response or transplant outcomes. Nonetheless, they correlated with overall survival, suggesting that while both IPSS‐M and the taxonomy capture disease biology, other non‐genetic factors may influence treatment response. RNA sequencing confirmed the biological distinctiveness of the taxonomy groups. Transcriptomic profiling of CD34+ bone marrow cells revealed unique, homogeneous gene expression patterns, particularly within the AML‐like, bi TET2 , SF3B1 , and TP53 ‐complex subgroups. Further integration of multi‐omics data may refine MDS classification, improving clinical decision‐making and guiding the development of targeted therapies.
Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex
Colin‐Leitzinger, Christelle, Tang, Yi-Han , Sherman, Seth, Zhang, Ling, Walker, Mary Ellen, Painter, Jeffrey S. , Abel, Gregory A., Baghdadi, Tareq Al, Deeg, H. Joachim, Foran, James M., Gore, Steven D., Harrington, Alexandra M., Kroft, Steven H. , Liu, Jane Jijun, Saber, Wael, Virani, Shamsuddin, Bejar, Rafael, Padron, Eric , Komrokji, Rami, DeZern, Amy E., Sekeres, Mikkael A., Colin, Christelle , Foran, James M , Gillis, Nancy , Otterstatter, Michael , Zhang, Ling , Moscinski, Lynn C. , Walker, Mary E. , Abel, Gregory A. , Deeg, H. Joachim , Foran, James M. , Gore, Steven D. , Saber, Wael , Bejar, Rafael , Lindsley, R Coleman , Walter, Matthew J , Komrokji, Rami, Dezern, Amy Elizabeth , Sekeres, Mikkael A.

Mayo Clinic

American Journal of Hematology | March 30, 2026 | Volume: 101 | Issue: 6 | Pages: 1407-1420

10.1002/ajh.70279 | PMID 41906220 Get It

ABSTRACT The epidemiology of myelodysplastic syndromes/neoplasms (MDS) is challenging to define due to inconsistent reporting, complex diagnostic procedures, and evolving diagnostic criteria. Using the National MDS Natural History Study—a prospective cohort with centrally adjudicated histopathology and genetic variant review—we characterized the landscape of MDS across the United States and identified differences across demographics. Among 2115 participants, 64% (1346) had an MDS spectrum condition, including MDS (24%), MDS/myeloproliferative neoplasm (5%) and precursor conditions—clonal cytopenia of undetermined significance (22%) and idiopathic cytopenia/dysplasia of undetermined significance (13%). The median age was 74 years, and participants were predominantly male (66%), White (91%), and Non‐Hispanic (92%). Myeloid‐associated variants were detected in 68% of participants, most commonly in TET2, DNMT3A, ASXL1, SF3B1, and SRSF2 . Black, compared to White, participants were younger at diagnosis (69 vs. 74 years, p = 0.01), had equal or increased prevalence of higher‐risk MDS, lower hemoglobin, and higher peripheral blood blasts, yet were less likely to receive MDS‐directed therapy (14% vs. 42%, p = 0.008). Black and Hispanic participants had fewer detectable gene mutations than White participants. Females had lower variant allele frequencies and fewer RNA splicing gene mutations than males. After multivariable adjustment, TP53 mutations, MDS diagnosis, and higher‐risk disease were associated with worse progression‐free and overall survival; age was also associated with overall survival. Black race trended toward improved progression‐free survival. These findings highlight the need for enhanced understanding of MDS pathogenesis across patient groups and refined prognostic tools to improve personalized management of MDS spectrum conditions. Trial Registration: ClinicalTrials.gov identifier: NCT02775383
Abstract PS5-07-20: Trial in progress: Phase 1 Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer (NCI Protocol #10546)
Leon-Ferre, R. A., Zahrieh, D. M., Advani, P. P., Giridhar, K. V., Dizona, P. J., Stover, D. G., Wang, X. , Tevaarwerk, A. J., Choong, G. M., Yasir, S., Kalari, K. R., Foldi, Julia , Parajuli, R., Hackney, Mary Helen , Chew, H. K., Wajeeha, R., Bear, H., Sharon, E., Ko, B., Shapiro, G. I., Gore, S., Pelosof, Lorraine, Wang, L., Goetz, M. P., Leon‐Ferre, Roberto A. , Zahrieh, David , Advani, P. P., Quiroga, Dionisia , Tevaarwerk, Amye J., Kalari, Krishna R. , Razaq, Wajeeha, Gore, Steven D. , Goetz, Matthew P.

Mayo Clinic

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PS5-07-20-PS5-07-20

10.1158/1557-3265.sabcs25-ps5-07-20 Get It

Abstract Background: DNA methyltransferase (DNMT) isoforms 1, 3A and 3B are enzymes that regulate DNA methylation, controlling gene expression, chromatin stability and genetic imprinting. We have previously shown that DNMT3A protein expression in early triple negative breast cancer (TNBC) is associated with more aggressive clinicopathologic features (higher tumor grade, tumor proliferation and frequency of nodal metastases) and worse clinical outcomes in the absence of chemotherapy (Leon-Ferre et al, SABCS 2024). Pre-clinically, we have shown that DNMT3A protein expression predicts sensitivity to DNMT inhibitors (Yu J et al., J Clin Invest 2018), and that DNMT inhibitor treatment leads to downregulation of DNMT3A, enhanced expression of immune-related pathways, and halted tumor growth, particularly in combination with immunotherapy and paclitaxel. Methods: This is a phase 1, open-label, multicenter study evaluating the safety and recommended phase 2 dose (RP2D) of the oral DNMT inhibitor ASTX727 + paclitaxel + pembrolizumab in metastatic TNBC. ASTX727 is an oral fixed dose combination (FDC) tablet of 35 mg decitabine (active agent) and 100 mg cedazuridine (a cytidine deaminase inhibitor that prevents decitabine degradation in the bowel and liver, allowing oral delivery). The study consists of two parts: Part 1 is a dose-finding cohort, using a 3+3 design, with 5 dose levels (Table), and its primary objective is to determine the RP2D. Part 2 is an expansion cohort (n=6), with the primary objective to confirm tolerability of the regimen at the RP2D. Secondary objectives are to record the antitumor activity of the regimen, describe the AE profile, explore the association of baseline gene expression profiles with clinical benefit, and to evaluate impact of treatment on tumor and ctDNA methylation. Exploratory objectives will evaluate the association of baseline DNMT3A protein expression and antitumor activity, and the impact of treatment on the tumor and peripheral blood immune phenotype. Eligible patients are adults 18 years or older with metastatic TNBC (ER/PR ≤10%, and HER2-negative per ASCO/CAP guidelines), independent of PD-L1 expression. Patients are allowed to have received 0-3 prior lines of systemic therapy in the metastatic setting, including prior immune checkpoint inhibitors in the early and/or metastatic settings. Patients must be eligible for taxanes and have adequate organ and bone marrow function. Patients with treated brain metastases are eligible if previously treated without evidence of progression after 4 weeks. Leptomeningeal carcinomatosis is not allowed. Patients must have an ECOG performance status of ≤2 and have no gastrointestinal disorders impacting absorption of oral medications. As of June 20, 2025, the study is enrolling patients, with 10 patients dosed in the dose-finding phase. Citation Format: R. Leon-Ferre, D. M. Zahrieh, P. P. Advani, D. Quiroga, K. V. Giridhar, P. J. Dizona, D. Stover, X. Wang, A. J. Tevaarwerk, G. M. Choong, S. Yasir, K. R. Kalari, J. Foldi, R. Parajuli, M. H. Hackney, H. K. Chew, R. Wajeeha, H. Bear, E. Sharon, B. Ko, G. I. Shapiro, S. Gore, L. Pelosof, L. Wang, M. P. Goetz. Trial in progress: Phase 1 Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer (NCI Protocol #10546) [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS5-07-20.
A novel approach to defining progression in MDS and precursor myeloid conditions in the MDS Natural History Study
DeZern, A. E., Otterstatter, Michael , Abel, Gregory A., Padron, Eric , Deeg, H. Joachim, Baghdadi, Tareq Al, Liu, Jane Jijun, Zhang, L, Kroft, Steven H. , Harrington, Alexandra M., Foran, J., Komrokji, Rami S., Starczynowski, Daniel T, Gore, Steven D, Saber, Wael, Bejar, Rafael, Lindsley, R. Coleman, Sherman, Seth, Lee, Cecilia , DiFronzo, Nancy, Sekeres, Mikkael A, Zhang, Ling , Gillis, Nancy , Otterstatter, Michael , Deeg, H Joachim , Zhang, Ling , Kroft, Steven H , Komrokji, Rami S , Bejar, Rafael , Lindsley, R Coleman , Sherman, Seth , Sekeres, Mikkael A , Baghdadi, Tareq Al , Dezern, Amy Elizabeth , Abel, Gregory A. , Deeg, H. Joachim , Xie, Zhuoer , Moscinski, Lynn C. , Foran, James M. , Komrokji, Rami S. , Starczynowski, Daniel T. , Gore, Steven D. , Saber, Wael , Walter, Matthew J , Sekeres, Mikkael A.

Mayo Clinic

Blood Advances | February 11, 2026 | Volume: 10 | Issue: 8 | Pages: 2743-2753

10.1182/bloodadvances.2025018770 | PMID 41671442 Get It

Abstract Patients at risk for progression from myeloid precursor states (idiopathic cytopenia of undetermined significance [ICUS] and clonal cytopenia of undetermined significance [CCUS]) to myelodysplastic syndrome (MDS) are not well defined. Epidemiologic risk factors, clonal changes for MDS development, and evolution from one MDS state to another were available in the MDS Natural History Study (NHS), a prospective cohort enrolled at diverse US sites. Extensive clinical data and biospecimens were collected at baseline and follow-up. A total of 1177 (56%) individuals with MDS or MDS-related precursor conditions (ICUS/idiopathic dysplasia of undetermined significance [IDUS], CCUS, and MDS/myeloproliferative neoplasm overlap) were enrolled and diagnosed in the MDS NHS. The median age was 74 years, with 89% aged ≥60 years, and most were male patients. Median follow-up time was 1.6 years and was similar among ICUS/IDUS, CCUS, and MDS. During follow-up period, 68% of participants terminated the study, 35% died, and 38% had disease progression. Using a refined clinical definition of progression, the greatest proportion of progression was observed among higher-risk-MDS (116 [73%]), followed by lower-risk-MDS (170 [52%]); fewer progression events were observed among participants with CCUS (65 [22%]) and ICUS/IDUS (46 [17%]). Predictors of progression are delineated, including female sex, higher quantity of mutations, the presence of TP53 mutation, and poor/very poor cytogenetic score. Based on these prospective data, guidelines for clinical management including monitoring and surveillance are outlined. The MDS NHS provides real-world data to illustrate how clinical and genotypic differences inform the classification, disease course, and approach to therapy, with informed monitoring guidelines for patients. This trial was registered at www.ClinicalTrials.gov as NCT02775383.
Toxicities on the E1910 phase III randomized trial of blinatumomab plus chemotherapy in adults with BCR:ABL-1 negative acute lymphoblastic leukemia
Advani, Anjali, Chen, Li, Sun, Zhuoxin, Mattison, Ryan, Paietta, Elisabeth, Zhang, Yanming, Racevskis, Janis, Lazarus, Hillard, Rowe, Jacob, Arber, Dan, Wieduwilt, Matthew, Liedtke, Michaela, Bergeron, Julie, Wood, Brent, Pratz, Keith, Dinner, Shira, Frey, Noelle, Gore, Steven, Bhatnagar, Bhavana, Atallah, Ehab, Uy, Geoffrey, Jeyakumar, Deepa, Lin, Tara, Willman, Cheryl, Podoltsev, Nikolai, Deangelo, Daniel, Patel, Shejal, Elliott, Michelle, Tzachanis, Dimitrios, Vachhani, Pankit, Bhave, Rupali, Sharon, Elad, Little, Richard, Erba, Harry, Stone, Richard, Luger, Selina, Mullighan, Charles, Tallman, Martin, Litzow, Mark, Advani, Anjali, Chen, Li, Sun, Zhuoxin, Mattison, Ryan, Paietta, Elisabeth, Zhang, Yanming, Racevskis, Janis, Lazarus, Hillard, Rowe, Jacob, Arber, Dan, Wieduwilt, Matthew, Liedtke, Michaela, Wood, Brent, Pratz, Keith, Dinner, Shira, Frey, Noelle, Gore, Steven, Bhatnagar, Bhavana, Atallah, Ehab, Uy, Geoffrey, Jeyakumar, Deepa, Lin, Tara, Willman, Cheryl, Podoltsev, Nikolai, Deangelo, Daniel, Patel, Shejal, Elliott, Michelle, Tzachanis, Dimitrios, Vachhani, Pankit, Bhave, Rupali, Sharon, Elad, Little, Richard, Erba, Harry, Stone, Richard, Luger, Selina, Mullighan, Charles, Tallman, Martin, Litzow, Mark

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 5120-5120

10.1182/blood-2025-5120 Get It

Abstract E1910 evaluated the addition of blinatumomab to chemotherapy in adults with B-acute lymphoblastic leukemia (ALL). The addition of blinatumomab in patients (pts) with measurable residual disease (MRD) negative (neg) B-ALL significantly improved both relapse-free and overall survival (NEJM 2024; 391: 320-33)1. Given the increasing use of blinatumomab and the E1910 backbone chemotherapy regimen, we evaluated > Grade 3 toxicities on this trial in further detail. We assessed toxicity among the MRD-neg pts by age, gender, body mass index (BMI), combined cytogenetic-molecular risk, and number of cycles of blinatumomab received. We also evaluated toxicities during induction since this trial used a modified chemotherapy backbone. Methods: The eligibility, combined cytogenetic-molecular risk, and treatment have been previously described.1 All toxicities were > Grade 3 by CTCAE version 4 with at least a possible relationship to treatment. Descriptive statistics were used to summarize the occurrence and rates of toxicities and Fisher's exact test was used to compare differences in proportions between groups. Analysis of induction included all pts who started treatment. Analysis of Step 3 toxicities included MRD-neg pts who started treatment on the blinatumomab (n=111) or chemotherapy only arm (n=112). Results: Pt characteristics: For induction (n=488), median age was 51 years (yrs) (range 30-70); 48.6% female. Combined cytogenetic-molecular risk: favorable (13.5%); intermediate (12.9%); no risk assigned (16.2%); unfavorable (57.4%). For induction, we compared toxicities for E1910 (n=488) to pts treated on a prior young adult study (n=289) (C10403) (Blood Adv 2021; 5(2): 504-12). The incidence of hyperglycemia (8% vs. 31.1%, p< 0.001), aspartate aminotransferase (AST) increase (6.1% vs. 12.8%, p=0.002), alanine aminotransferase increase (ALT) (11.7% vs. 28.7%, p< 0.001), and hyperbilirubinemia (11% vs. 19%, p=0.002) were significantly lower in E1910 pts. The incidence of pancreatitis (1.8%), thromboembolic events (4.5%), and febrile neutropenia (25.4%) in E1910 was similar to C10403. Toxicities in the MRD-neg pts in the blinatumomab arm (n=111): Despite a high incidence of neutropenia (74.8%) and thrombocytopenia (55.9%) in Step 3, there was a relatively low incidence of sepsis (7.2%), bacteremia (1.8%), cytokine release syndrome (CRS) (3.6%) and neurologic adverse events (0-6.3%). There was a higher incidence of neurological or psychiatric events in the blinatumomab arm (23%) versus chemotherapy arm (5%) (p < 0.001) when all events were combined. There was a numerically higher incidence of ataxia (4.4% vs. %, p=0.16) and dysphasia (11.1% vs. 3%, p=0.12) in pts > 55 yrs and a higher incidence of neutropenia (80.3% vs. 66.7%, p=0.12) and thrombocytopenia (62.1% vs. 46.7%, p=0.12) in the younger pts (age < 55 yrs). In pts with a BMI < 30 kg/m2 (vs. > 30 kg/m2), there was a significantly higher incidence of leukopenia (51.7% vs. 26.4%, p=0.007) and thrombocytopenia (65.5% vs. 45.3%, p=0.037). However, this did not translate into an increased incidence of bleeding or infectious complications. By gender, females had a higher numerical incidence of AST increase (8.8% vs. 0%, p=0.057) and CRS (7% vs. 0% p=0.12); whereas males had a higher incidence of catheter- related infections (7.4% vs. 0%, p=0.05) and hyperglycemia (11.1% vs. 3.5%, p=0.16). A little more than half (56.8%) of pts received 4 cycles of blinatumomab with the remainder of pts receiving 1 (10.8%), 2 (28.8%), or 3 cycles (3.6%). Pts receiving 3-4 cycles of blinatumomab vs. 1-2 cycles of blinatumomab had a statistically higher incidence of anemia (38.8% vs. 6.8%, p< 0.001), neutropenia (98.5% vs. 38.6%, p< 0.001), and thrombocytopenia (83.6% vs. 13.6%, p< 0.001), likely related to being on treatment for a longer period of time. Conclusions: Blinatumomab was well tolerated with no significant toxicity differences noted by age, gender, or number of cycles of blinatumomab received. Pts with a lower BMI did have an increased incidence of leukopenia and thrombocytopenia, possibly related to flat dosing of the drug. However, this did not translate into increased complications. Toxicites during induction were notably few, which suggests that this backbone with age adjustments may serve as a good backbone for future trials. Blinatumomab is being evaluated with low dose chemotherapy and other targeted agents in ongoing trials.
Myeloid malignancies molecular analysis for therapy choice (myeloMATCH): Rapid availability of clinical, pathologic and molecular features for treatment assignment in the first 550 patients.
Winer, Eric, Tsai, Stephanie, Osman, Afaf, Im, Annie , Moseley, Anna , Wood, Brent, Chen, Xueyan , Qu, Xiaoyu , Harris, Lyndsay N. , Ghatak, Sayak , Gore, Steven D. , Michaelis, Laura C. , Odenike, Olatoyosi , Stone, Richard M. , Luger, Selina M. , Assouline, Sarit, Litzow, Mark R. , Lachowiez, Curtis A. , Borate, Uma , Savoie, Mary Lynn , Roy, Ntasha, Radich, Jerald P. , Little, Richard F. , Othus, Megan , Atallah, Ehab , Tsai, Stephanie, Sabloff, Mitchell , Loghavi, Sanam , Fang, Min, Yeung, Cecilia C.S. , Uy, Geoffrey L. , Erba, Harry Paul , Litzow, Mark R. , Reagan, John L. , Jonas, Brian A. , Jiwani, Shahanawaz S.

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 5279-5279

10.1182/blood-2025-5279 Get It

Abstract Background: MyeloMATCH is an NCI-sponsored initiative for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) employing a Master Screening and Reassessment Protocol (MSRP) to assign patients (pts) to a pt and disease biology-specific clinical trial. Several trials evaluating initial therapies are currently open, while subsequent trials dedicated to eradicating measurable residual disease during consolidation and including stem cell transplant are being developed. A pt enrolled at diagnosis may be followed longitudinally and be eligible for trials in sequential tiers throughout the treatment course. We report key data concerning the first cohort of pts enrolled on the MSRP. Methods: After pts with suspected AML or MDS consent for the MSRP, blood and marrow are sent to the myeloMATCH Molecular Diagnostics Network (MDNet) of central CLIA labs operating under a single Investigational Device Exemption to rapidly define molecular, cytogenetic, and immunophenotypic characteristics. These data are catalogued by a bioinformatics team (MATCHBox) and reviewed daily to assign participants to an available trial based on pt and disease features. A Tier Advancement Pathway (TAP) allows standard of care therapy with potential for assignment to subsequent myeloMATCH trials. Since activation in May 2024, 550 patients age≥18 were enrolled on the MSRP from 76 institutions: 48 Academic, 14 NCORP, 11 community, 3 VA. There are currently 4 open randomized AML trials (≥age 60 or unfit with mutant FLT3, ≥age 60 IDH2 mutant AML, fit age<60 ELN 2017 intermediate-risk AML, fit age<60 ELN 2017 adverse risk) and 1 MDS trial(IDH2 mutant). Patients not eligible for an open protocol were assigned to TAP. Results: Of the 550 pts consented, 491 completed screening assays; 49 had no or incomplete samples; 10 withdrew before completed analysis. Median cytogenetic turnaround time (TAT) was 69 hours (91% within 72 hours), and median Next Generation Sequencing (NGS) TAT from receipt was 49 hours (95% within 72 hours). Seventy-six pts (of 491 with assay data) were not assigned due to non-AML or non-MDS diagnoses, the most common being: B-ALL [n=11], MPN [9], benign marrow [9], APML [7], and MPAL [6]. The AML/MDS verified cohort was 415 pts, 366 (89.2%) patients with AML (45% age <60) and 49 (11.8%) with MDS. The median age at screening was 63 years (range:18-95) and 186 (45%) were female. Eighty-two percent identified as White, 7.5% Black, 3% Asian, 7% unknown, and 9% as Hispanic. The most frequent mutations in the AML pts were NPM1 (24.0%), DNMT3A (22.7%), TET2 (19.9%), NRAS (18.0%), FLT3 (18.0% ITD, TKD 7.1%), TP53 (14.5%), and CEBPA (8.7%); IDH1/2 mutation rates were 8.2% and 13.7%, respectively. Co-mutations include FLT3/NPM1 (9.8%), NPM1/IDH2 (4.4%), IDH1/2 and any RAS (3.8%). Karyotypes were normal in 40.4%, complex 20.8%, inv(16) 6.0%, MLL/KMT2A 4.6% and t(8;21) 1.9%. 29% had favorable risk disease, 29% intermediate, and 42% adverse (ELN 2017). In MDS, mutations included: TP53 (36.7%), RUNX1 (20.4%) ASXL1 (20.4%), TET2 (18.4%), spliceosome mutations (SRSF2, SF3B1, U2AF1 and ZRSR2, 28.6%) andIDH1/2 in 4.1% and 6.1%, respectively. Karyotypes were normal in 24.5%; complex in 40.8%. By IPSS-R, 2.4% were low, 73.8% intermediate, 2.4% high, and 21.4% very high risk. 82/415 (20%) pts were assigned to initial therapy protocol, with an increase in assignment rate to 44% in the most recent two months. 71/415 pts (16%) were enrolled in one of the MyeloMATCH studies. Three-hundred forty-four pts (80%) were assigned and enrolled to TAP (296 AML, 48 MDS) for potential assignment to subsequent tier trials. In the TAP AML pts, 99 (33%) have completed initial treatment, including intensive chemotherapy (IC) in 62% of pts and hypomethylating agents/venetoclax (HMA/VEN) in 38%. In pts <60 years of age, 87% received IC v. 13% with HMA/VEN, in >60 34% IC v. 66% HMA/VEN and in age 60-75 42% IC v. 58% HMA/Ven. Conclusion: MyeloMATCH has screened over 500 pts from academic and community sites in the US and Canada in 14 months, meeting the TAT goal of sample acquisition to results of <72 hours. Assignment to treatment protocols has substantially increased recently. As additional trials open (12 in development) we expect the percentage of pts enrolled on MSRP who go on to therapeutic trials will markedly increase, thereby allowing a personalized medicine approach for a broad group of US and Canadian adult pts with AML and MDS.
Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial
Zhong, Xiaoming , Sun, Zhuoxin , Wei, Huimei, Chang, Ti‐Cheng , Lei, Shaohua, Rampersaud, Evadnie , Fan, Yiping, Wu, Gang , Mattison, Ryan J. , Zhang, Yanming , Racevskis, Janis, Rowe, Jacob M. , Wieduwilt, Matthew J. , Liedtke, Michaela , Bergeron, Julie , Pratz, Keith W. , Dinner, Shira, Frey, Noelle, Gore, Steven D. , Bhatnagar, Bhavana , Jeyakumar, Deepa , Patel, Shejal, Elliott, Michelle A. , Vachhani, Pankit , Roy, Rupali , Little, Richard F. , Stone, Richard M. , Tallman, Martin S. , Paietta, Elisabeth, Luger, Selina M. , Litzow, Mark R. , Roberts, Kathryn G. , Montefiori, Lindsey E. , Pölönen, Petri , Zhang, Wenchao, Lazarus, Hillard M. , Arber, Daniel A. , Wood, Brent L. , Frey, Noelle, Atallah, Ehab , Uy, Geoffrey L. , Lin, Tara L. , Willman, Cheryl L. , Podoltsev, Nikolai , DeAngelo, Daniel J. , Advani, Anjali S. , Tzachanis, Dimitrios , Sharon, Elad , Erba, Harry Paul , Yang, Jun J.J. , Mullighan, Charles G.

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 31-31

10.1182/blood-2025-31 Get It

Abstract Introduction:A comprehensive integration of significantly mutated genes and pathways with molecular subgroups is lacking in adult B-ALL. Furthermore, the genomic drivers underlying each subgroup remain to be identified.We aimed to perform genomic analysis on a large cohort of patients with adult B-ALL, and to correlate genomic markers with achievement of MRD negativity enabling blinatumomab randomization, and with subsequent response to blinatumomab. Methods:For genomic analysis, we studied 569 adults with newly diagnosed B-ALL registered for initial screening on the ECOG-ACRIN-led E1910 trial (NCT02003222), which evaluated the addition of blinatumomab to standard consolidation chemotherapy. The median age was 52 yrs (range 30 to 71 yrs), with 52% males. Analysis was performed on tumor and matched-normal samples using whole transcriptome sequencing (RNA-seq; tumor only; n=569), whole exome sequencing (n=490), whole genome sequencing (n=131), and single nucleotide polymorphism array (n=445). B-ALL cases were classified into 22 molecular groups. Outcome analysis was limited to patients enrolled and treated on E1910 (n=319). Results: Driver genes (n=268) were identified by the mutation-significance detection tool dNdScv or by the presence of pathogenic variants in known cancer genes, with NUP188 identified as a novel driver gene. Recurrently mutated pathways included: B-cell development (46%), cell cycle (44%), epigenetic regulation (30%), other transcriptional regulation (27%), Ras signaling (25%), RNA machinery (17%) and JAK-STAT signaling (8%). A high frequency of high-risk subtypes was observed including BCR::ABL1 (20%), BCR::ABL1-like (18%), low hypodiploid (14%) and KMT2A (12%). Using tSNE analysis, we identified a new cluster of cases (n=20, 3.5%) lacking a known subgroup driver, with overexpression of CEBPA (n=13) or CEBPB (n=7), distinct from CEBPE/ZEB2, termed “CEBP-altered” ALL (CEBPalt). Five of 13 cases with high CEBPA expression harbored an IGH::CEBPA rearrangement and one harbored a RXRA::CEBPA enhancer hijacking alteration. Of the 7 cases with high CEBPB expression, 5 harbored IGH::CEBPB, and two of these had concomitant clonal BCR::ABL1 fusions. To identify additional mechanisms of CEBP deregulation, in situ Hi-C coupled to H3K27 acetylation immunoprecipitation (HiChIP) was performed on 5 cases. Four cases showed evidence of de novo CEBPA enhancer activity. In two cases, we identified novel insertions (12 and 34nt) ~2kb downstream of CEBPA. A novel translocation and enhancer hijacking event between LINC00426 and the 5' UTR of CEBPB was identified in the remaining case. Overall, we confirmed genomic alterations of CEBPA or CEBPB in 16 of 20 cases with available material. Thus, we have identified a new molecular subgroup of adult B-ALL characterized by genomic alterations that drive enhancer hijacking and oncogenic deregulation of CEBPA/CEBPB. Several subgroups were enriched in patients that failed induction chemotherapy (n=62) or were MRD-positive (n=63) compared to those that achieved MRD-negative status (n=194): BCR::ABL1-like (30 vs 14%, p<0.001), KMT2A (18 vs 9%, p=0.03) and BCL2/MYC (5 vs 1%, p=0.06). Conversely, the following subgroups were enriched in patients that achieved MRD-negativity: PAX5alt (6 vs 18%, p=0.002), TCF3::PBX1 (0 vs 5%, p=0.01) and ZNF384 (2 vs 6%, p=0.08) Within each molecular subgroup we compared the survival of patients who achieved MRD-negative status after induction and were randomized to receive blinatumomab plus chemotherapy (n=93) or chemotherapy only (n=91). Although numbers were low, blinatumomab improved relapse-free survival for patients with hyperdiploid, PAX5alt, BCR::ABL1-like and KMT2A ALL compared to chemotherapy alone. Clonal hematopoiesis of indeterminate potential (CHIP)-related gene mutations were identified in 121 of 417 cases analyzed (29% total: somatic 74%, remission 31%, both 5%). TP53 mutations were most frequent (n=65 patients), with the majority identified in patients with low hypodiploid (n=52). Interestingly, patients with CRLF2 rearrangements collectively harbored the highest number of other CHIP gene mutations (n=13), including DNMT3A (n=4), TET2 (n=3) and ASXL1 (n=3). Conclusions:We provide a comprehensive landscape of genomic alterations in adult B-ALL and identify a new group characterized by deregulation of CEBPA/CEBPB (CEBPalt). We also provide insights into the efficacy of blinatumomab in different molecular subgroups of adult B-ALL.